EnteroBiotix Completes Enrolment in Phase 2a Trial of Microbiome Therapy Before Stem Cell Transplant

EnteroBiotix has announced the completion of patient enrolment in the Phase 2a MAST clinical trial evaluating its microbiome therapy EBX 102 02 in individuals preparing for allogeneic haematopoietic stem cell transplantation. The investigator initiated study has recruited 50 adult patients with haematological malignancies who are scheduled to receive a transplant.

The trial is designed to assess whether restoring the gut microbiome before transplantation may improve clinical outcomes. Patients undergoing stem cell transplantation often experience major disruption to their intestinal microbiota due to chemotherapy, antibiotics and conditioning regimens. This imbalance has been associated with complications including infections and graft versus host disease.

EBX 102 02 is an orally delivered full spectrum microbiome therapeutic intended to restore microbial diversity in the gut. By re establishing a healthier microbiome prior to transplant, researchers hope to support immune recovery and reduce treatment related complications.

The study is being conducted in collaboration with academic investigators and transplant specialists. Completion of enrolment marks an important milestone for the programme, and EnteroBiotix expects the trial to generate data that will help guide future development of microbiome based therapies in high risk transplant settings.